Skip to main content
Erschienen in:

01.08.2005 | Leitthema

Möglichkeiten der palliativen Therapie des Rektumkarzinoms

verfasst von: J. Stöhlmacher, Prof. Dr. C. Bokemeyer

Erschienen in: Die Onkologie | Ausgabe 8/2005

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Möglichkeiten zur Behandlung des fortgeschrittenen rektalen Karzinoms sind in den letzten Jahren spürbar gewachsen. Die folgende Übersicht stellt die aktuellen Therapiemodalitäten in der palliativen Situation zusammenfassend dar. Fokussiert wird dabei auf die chemotherapeutischen Optionen mit Irinotecan, Oxaliplatin und Fluoropyrimidinen sowie den Stellenwert der sog. Targeted-Therapie. Hierbei finden besondere Berücksichtigung der Inhibitor des epidermalen Wachstumsfaktor-Rezeptors (EGFR) Cetuximab und der in die Prozesse der Angiogenese eingreifende Antikörper Bevacizumab. Des Weiteren werden der Stellenwert der primären und sekundären Metastasektomie im palliativen Gesamtkonzept und die Bedeutung der Strahlentherapie in der primären Behandlung des rektalen Tumors diskutiert.
Literatur
1.
Zurück zum Zitat Douillard JY, Cunningham D, Roth AD et al. (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer. A multicenter randomised trial. Lancet 355:1041–1047CrossRefPubMed Douillard JY, Cunningham D, Roth AD et al. (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer. A multicenter randomised trial. Lancet 355:1041–1047CrossRefPubMed
2.
Zurück zum Zitat Saltz LB, Cox JV, Blanke C et al. (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905–914CrossRefPubMed Saltz LB, Cox JV, Blanke C et al. (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905–914CrossRefPubMed
3.
Zurück zum Zitat Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19:3801–3807PubMed Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19:3801–3807PubMed
4.
Zurück zum Zitat Ando Y, Saka H, Ando M et al. (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:6921–6926PubMed Ando Y, Saka H, Ando M et al. (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:6921–6926PubMed
5.
Zurück zum Zitat de Gramont A, Figer A, Seymour M et al. (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947PubMed de Gramont A, Figer A, Seymour M et al. (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947PubMed
6.
Zurück zum Zitat Tournigand C, Andre T, Achille E et al. (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237PubMed Tournigand C, Andre T, Achille E et al. (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237PubMed
7.
Zurück zum Zitat Grothey A, Jordan K, Kellner O et al. (2003) Randomized phase II trial of capecitabine plus irinotecan (CapIri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC). Prog Proc Am Soc Clin Oncol 22:255 (Abstract) Grothey A, Jordan K, Kellner O et al. (2003) Randomized phase II trial of capecitabine plus irinotecan (CapIri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC). Prog Proc Am Soc Clin Oncol 22:255 (Abstract)
8.
Zurück zum Zitat Goldberg RM, Sargent DJ, Morton RF et al. (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30PubMed Goldberg RM, Sargent DJ, Morton RF et al. (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30PubMed
9.
Zurück zum Zitat Cunningham D, Humblet Y, Siena S et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345PubMed Cunningham D, Humblet Y, Siena S et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345PubMed
10.
Zurück zum Zitat Saltz L, Rubin M, Hochster H, Tchekmeydian NS, Waksal H, Needle M, LoBuglio A (2001) Cetuximab (IMC-C225) Plus Irinotecan (CPT-11) is Active in CPT-11-Refractory Colorectal Cancer (CRC) that Expresses Epidermal Growth Factor Receptor (EGFR). Prog Proc Am Soc Clin Oncol 20:7 (Abstract) Saltz L, Rubin M, Hochster H, Tchekmeydian NS, Waksal H, Needle M, LoBuglio A (2001) Cetuximab (IMC-C225) Plus Irinotecan (CPT-11) is Active in CPT-11-Refractory Colorectal Cancer (CRC) that Expresses Epidermal Growth Factor Receptor (EGFR). Prog Proc Am Soc Clin Oncol 20:7 (Abstract)
11.
Zurück zum Zitat Chung KY, Shia J, Kemeny NE et al. (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803–1810CrossRefPubMed Chung KY, Shia J, Kemeny NE et al. (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803–1810CrossRefPubMed
12.
Zurück zum Zitat Hurwitz H, Fehrenbacher L, Novotny W et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342CrossRefPubMed Hurwitz H, Fehrenbacher L, Novotny W et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342CrossRefPubMed
13.
Zurück zum Zitat Kabbinavar FF, Schulz J, McCleod M et al. (2003) Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11. J Clin Oncol 22 [Suppl]:3516 (Abstract) Kabbinavar FF, Schulz J, McCleod M et al. (2003) Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11. J Clin Oncol 22 [Suppl]:3516 (Abstract)
14.
Zurück zum Zitat Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987–989CrossRefPubMed Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987–989CrossRefPubMed
15.
Zurück zum Zitat Rothenberg ML, Oza AM, Bigelow RH et al. (2003) Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21:2059–2069CrossRefPubMed Rothenberg ML, Oza AM, Bigelow RH et al. (2003) Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21:2059–2069CrossRefPubMed
16.
Zurück zum Zitat Saltz LB, Lenz H, Kindler H et al. (2005) Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. In: Proceedings of the 2005 Gastrointestinal Cancers Symposium 2005:169b (Abstract) Saltz LB, Lenz H, Kindler H et al. (2005) Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. In: Proceedings of the 2005 Gastrointestinal Cancers Symposium 2005:169b (Abstract)
17.
Zurück zum Zitat Mitchell EP, Alberts SR, Schwartz MA et al. (2005) High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 In: Proceedings of the 2005 Gastrointestinal Cancers Symposium 2005:169a (Abstract) Mitchell EP, Alberts SR, Schwartz MA et al. (2005) High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 In: Proceedings of the 2005 Gastrointestinal Cancers Symposium 2005:169a (Abstract)
18.
Zurück zum Zitat Maindrault-Goebel F, Tournigand C, Andre T, Carola E, Mabro M, Artru P, Louvet C, de Gramont A (2004) Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol 15:1210–1214CrossRefPubMed Maindrault-Goebel F, Tournigand C, Andre T, Carola E, Mabro M, Artru P, Louvet C, de Gramont A (2004) Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol 15:1210–1214CrossRefPubMed
19.
Zurück zum Zitat Hartley JE, Lopez RA, Paty PB, Wong WD, Cohen AM, Guillem JG (2003) Resection of locally recurrent colorectal cancer in the presence of distant metastases: can it be justified? Ann Surg Oncol 10:227–233 Hartley JE, Lopez RA, Paty PB, Wong WD, Cohen AM, Guillem JG (2003) Resection of locally recurrent colorectal cancer in the presence of distant metastases: can it be justified? Ann Surg Oncol 10:227–233
20.
Zurück zum Zitat Tejero E, Fernandez-Lobato R, Mainar A, Montes C, Pinto I, Fernandez L, Jorge E, Lozano R (1997) Initial results of a new procedure for treatment of malignant obstruction of the left colon. Dis Colon Rectum 40:432–436 Tejero E, Fernandez-Lobato R, Mainar A, Montes C, Pinto I, Fernandez L, Jorge E, Lozano R (1997) Initial results of a new procedure for treatment of malignant obstruction of the left colon. Dis Colon Rectum 40:432–436
21.
Zurück zum Zitat Farouk R, Ratnaval CD, Monson JR, Lee PW (1997) Staged delivery of Nd:YAG laser therapy for palliation of advanced rectal carcinoma. Dis Colon Rectum 40:156–160 Farouk R, Ratnaval CD, Monson JR, Lee PW (1997) Staged delivery of Nd:YAG laser therapy for palliation of advanced rectal carcinoma. Dis Colon Rectum 40:156–160
22.
Zurück zum Zitat Crane CH, Janjan NA, Abbruzzese JL et al. (2001) Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer. Int J Radiat Oncol Biol Phys 49:107–116CrossRefPubMed Crane CH, Janjan NA, Abbruzzese JL et al. (2001) Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer. Int J Radiat Oncol Biol Phys 49:107–116CrossRefPubMed
23.
Zurück zum Zitat Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. 230:309–321 Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. 230:309–321
24.
Zurück zum Zitat Lehnert T, Knaebel HP, Duck M, Bulzebruck H, Herfarth C (1999) Sequential hepatic and pulmonary resections for metastatic colorectal cancer. Br J Surg 86:241–243CrossRefPubMed Lehnert T, Knaebel HP, Duck M, Bulzebruck H, Herfarth C (1999) Sequential hepatic and pulmonary resections for metastatic colorectal cancer. Br J Surg 86:241–243CrossRefPubMed
25.
Zurück zum Zitat Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, Kunstlinger F, Levi F, Bismuth F (2001) Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 8:347–353PubMed Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, Kunstlinger F, Levi F, Bismuth F (2001) Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 8:347–353PubMed
26.
Zurück zum Zitat Pozzo C, Basso M, Cassano A et al. (2004) Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 15:933–939CrossRefPubMed Pozzo C, Basso M, Cassano A et al. (2004) Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 15:933–939CrossRefPubMed
27.
Zurück zum Zitat Ruan DT, Warren RS (2005) Liver-directed therapies in colorectal cancer. Semin Oncol 32:85–94PubMed Ruan DT, Warren RS (2005) Liver-directed therapies in colorectal cancer. Semin Oncol 32:85–94PubMed
28.
Zurück zum Zitat Kerr DJ, McArdle CS, Ledermann J et al.; Medical Research Council’s colorectal cancer study group; European Organisation for Research and Treatment of Cancer colorectal cancer study group (2003) Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 361:368–373CrossRefPubMed Kerr DJ, McArdle CS, Ledermann J et al.; Medical Research Council’s colorectal cancer study group; European Organisation for Research and Treatment of Cancer colorectal cancer study group (2003) Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 361:368–373CrossRefPubMed
29.
Zurück zum Zitat Wu JS, Wong R, Johnston M, Bezjak A, Whelan T; Cancer Care Ontario Practice Guidelines Initiative Supportive Care Group (2003) Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 55:594–605CrossRefPubMed Wu JS, Wong R, Johnston M, Bezjak A, Whelan T; Cancer Care Ontario Practice Guidelines Initiative Supportive Care Group (2003) Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 55:594–605CrossRefPubMed
30.
Zurück zum Zitat Farnell GF, Buckner JC, Cascino TL, O’Connell MJ, Schomberg PJ, Suman V (1996) Brain metastases from colorectal carcinoma. The long term survivors. Cancer 78:711–716CrossRefPubMed Farnell GF, Buckner JC, Cascino TL, O’Connell MJ, Schomberg PJ, Suman V (1996) Brain metastases from colorectal carcinoma. The long term survivors. Cancer 78:711–716CrossRefPubMed
Metadaten
Titel
Möglichkeiten der palliativen Therapie des Rektumkarzinoms
verfasst von
J. Stöhlmacher
Prof. Dr. C. Bokemeyer
Publikationsdatum
01.08.2005
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 8/2005
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-005-0916-3

Weitere Artikel der Ausgabe 8/2005

Der Onkologe 8/2005 Zur Ausgabe

Algorithmus + Klassifikation

Algorithmus zum Thema Rektumkarzinom

Onkologie im Internet

Webadressen zum Rektumkarzinom

Neu im Fachgebiet Onkologie

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Endometriose-Subtypen und das Risiko für Ovarialkarzinome

19.07.2024 Ovarialkarzinom Nachrichten

US-Kohortendaten sprechen dafür, dass verschiedene Endometrioseformen unterschiedlich mit dem Risiko für Ovarialkarzinome assoziiert sind. Besonders erhöht ist das Risiko offenbar bei tief infiltrierenden und ovariellen Endometrioseformen.

Die zelluläre Differenzierung wird wiederhergestellt

18.07.2024 Akute myeloische Leukämie Nachrichten

Ivosidenib von Servier ist ein Inhibitor der mutierten Isoform der Isocitrat-Dehydrogenase-1 (IDH1) und wird zur Behandlung von Patientinnen und Patienten mit neu diagnostizierter akuter myeloischer Leukämie (AML) eingesetzt. Die Substanz sorgt für die Wiederherstellung der zellulären Differenzierung.

Weißer Hautkrebs: Ein Update zu Diagnostik und Therapie

18.07.2024 Fortbildungswoche 2024 Kongressbericht

In der aktualisierten Version der S3-Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ gibt es neue Empfehlungen, unter anderem zu erweiterten Optionen bei aktinischer Keratose sowie zur systemischen und chirurgischen Behandlung von Plattenepithelkarzinomen. Ein Überblick.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.